2-(4-羟基-3-甲氧基苯基)噻唑烷 | 98896-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-(4-羟基-3-甲氧基苯基)噻唑烷
• 中文别名: 2-甲氧基-4-(2-噻唑烷基)苯酚
• 英文名称: 2-(4-hydroxy-3-methoxyphenyl)thiazolidine
• 英文别名: 2-methoxy-4-(thiazolidin-2-yl)phenol；2-(4-hydroxy-3-methoxyphenyl)-1,3-thiazolane；2-Methoxy-4-(1,3-thiazolidin-2-yl)phenol
• CAS: 98896-96-9
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.285
• InChiKey: ARBGBCQCAFWNDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(4-羟基-3-甲氧基苯基)噻唑烷 在 吡啶 、 氢氧化钾 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 [4-(3-Benzoyl-thiazolidin-2-yl)-2-methoxy-phenoxy]-acetic acid
  参考文献：
  名称：

  新型噻唑烷衍生物作为血栓烷A2受体拮抗剂的合成和评价。

  摘要：

  合成了一系列的3-苯甲酰基或3-苯磺酰基-2-取代的噻唑烷衍生物，并评估了它们对（15S）-15-羟基-11α，9α-（环氧甲烷）的血栓烷A2（TXA2）受体拮抗作用。 prosta-5（Z），13（E）-二烯酸（U-46619）诱导的兔富血小板血浆（PRP）聚集。一个简单的2-芳基噻唑烷衍生物3-苯甲酰基-2-（4-羟基-3-甲氧基苯基）噻唑烷（5a）显示出适度的TXA2受体拮抗剂活性。5a的修饰导致2-氯-4- [3-（4-氯苯基磺酰基）噻唑烷-2-基甲基基]苯氧基乙酸（29d），它的有效TXA2受体拮抗剂活性是5a的10倍。

  DOI：

  10.1248/cpb.42.521
• 作为产物：
  描述：

  半胱胺盐酸盐 以64%的产率得到
  参考文献：
  名称：

  IVATA, TYUDZO;IMANISI, TAKEHSI;MITSUMURA, TSUTOMU;KODZAVA, YASUXIRO;TIBA,+

  摘要：

  DOI：

文献信息

• [EN] NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] NOUVELLES MÉTHODES DE TRAITEMENT DES MALADIES INFLAMMATOIRES
  申请人：CORTICAL PTY LTD

  公开号：WO2004089927A1

  公开（公告）日：2004-10-21

  Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

  提供了抑制巨噬细胞迁移抑制因子（MIF）细胞因子或生物活性的方法，包括将MIF与式（I）化合物接触。该发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病况的方法，包括给予式（I）化合物的治疗，可以单独使用或作为联合疗法的一部分。还提供了式（I）的新化合物。
• NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR
  申请人：Chung Hae Young

  公开号：US20140037564A1

  公开（公告）日：2014-02-06

  Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  提供了一种具有美白皮肤、抗氧化和PPAR活性的新化合物及其医药用途，该化合物具有抑制酪氨酸酶的美白皮肤活性，因此适用于用于美白皮肤的药用组合物或化妆品；具有抗氧化活性，因此适用于预防和治疗皮肤衰老；具有PPAR活性，特别是PPARα和PPARγ活性，因此适用于用于预防和治疗肥胖、代谢性疾病或心血管疾病的药用组合物或保健食品。
• Platelet anti-aggregant activity of 2,2-dimethylthiazolidine hydrochloride and 2-(4-hydroxy-3-methoxyphenyl)thiazolidine.
  作者：TSUTOMU MIMURA、YASUHIRO KOHAMA、SHIGEKI KUWAHARA、KOHJI YAMAMOTO、YUTAKA KOMIYAMA、MIKIO SATAKE、YOSHIYUKI CHIBA、KAZUYUKI MIYASHITA、TETSUAKI TANAKA、TAKESHI IMANISHI、CHUZO IWATA

  DOI：10.1248/cpb.36.1110

  日期：——

  The characteristics of platelet anti-aggregant activity of 2, 2-dimethylthiazolidine hydrochloride (I) and 2-(4-hydroxy-3-methoxyphenyl)thiazolidin (II) have been evaluated. Compounds I and II were potent inhibitors of collagen- and arachidonic acid-induced aggregation of rat and rabbit platelets (IC50 or IC100 values : 10-5-10-4 M), while they were less effective in the cases of adenosine 5'-diphosphate 2Na, A-23187 and labile aggregation-stimulating substance. Also, both compounds inhibited platelet shape change induced by a low concentation of arachidonic acid. Compounds I (100μM) and II (25μM) significantly inhibited serotonin release and thromboxane B2 formation induced by arachidonic acid in rabbit platelets. Compound I (100μM) inhibited prostaglandin I2 formation in rat aorta, but II (100μM) did not. In contrast, neither compound had any effect on platelet adhesiveness. These results strongly suggest that I and II prevented platelet aggregation, shape change and serotonin release reaction via their inhibitory effects on arachidonic acid metabolism of platelets, and the inhibiting potency of II was higher than that of I.

  对 2，2-二甲基噻唑烷盐酸盐（I）和 2-（4-羟基-3-甲氧基苯基）噻唑烷（II）的血小板抗聚集活性特征进行了评估。化合物 I 和 II 是胶原蛋白和花生四烯酸诱导的大鼠和兔血小板聚集的强效抑制剂（IC50 或 IC100 值：10-5-10-4 M），而对 5'-二磷酸腺苷 2Na、A-23187 和易变聚集刺激物质的抑制效果较差。此外，两种化合物都能抑制低浓度花生四烯酸引起的血小板形状变化。化合物 I（100μM）和 II（25μM）可明显抑制花生四烯酸诱导的兔血小板中血清素的释放和血栓素 B2 的形成。化合物 I（100μM）可抑制大鼠主动脉中前列腺素 I2 的形成，但 II（100μM）却没有抑制作用。相反，这两种化合物对血小板的粘附性都没有影响。这些结果有力地表明，I 和 II 是通过抑制血小板的花生四烯酸代谢作用来阻止血小板聚集、形状改变和血清素释放反应的，而且 II 的抑制效力高于 I。
• Novel methods for the treatment of inflammatory diseases
  申请人：Morand Francis Eric

  公开号：US20070010563A1

  公开（公告）日：2007-01-11

  Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

  本发明提供了抑制巨噬细胞迁移抑制因子（MIF）细胞因子或生物活性的方法，包括将MIF与式（I）化合物接触。本发明还涉及治疗MIF细胞因子或生物活性涉及的疾病或病症的方法，包括单独或作为联合治疗的一部分给予式（I）化合物。本发明还提供了新的式（I）化合物。
• Methods for the treatment of inflammatory diseases
  申请人：Cortical PTY LTD

  公开号：US07863313B2

  公开（公告）日：2011-01-04

  Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

  提供了抑制细胞因子或巨噬细胞迁移抑制因子（MIF）生物活性的方法，包括将MIF与式（I）的化合物接触。本发明还涉及治疗MIF细胞因子或生物活性参与的疾病或病况的方法，包括单独或作为联合治疗的一部分给予式（I）的化合物。还提供了式（I）的新化合物。